The Metabolic Risk in Newly Diagnosed @entity1 with XXXX is Related to Fat Distribution and Circulating Adipokines and Improves after Treatment.

@entity1 @entity14288 @entity442 @entity37462 @entity2012 @entity1254 @entity1675 @entity209 @entity1386 @entity1851
UNASSIGNED: @entity1386 ( @entity1386 ) distribution is closely related to @entity209 risk. GH reduces visceral and total body fat mass and induces whole body insulin resistance. Aims: To assess the effects of total and @entity1386 ( @entity1386 ) distribution and derived adipokines on systemic insulin resistance and lipid metabolism in @entity2012 . @entity1 : Seventy adult @entity1 with active @entity2012 (43 males, age 49    14 years) were evaluated before and a subset (n = 30, 20 males) was evaluated after treatment. Outcome Measures: Body composition and @entity1386 , glucose metabolism parameters, lipids, @entity1851 , and selected adipokines ( @entity14288 , @entity37462 , @entity1254 , and leptin) were measured. Results: At baseline @entity1386 was positively associated with glucose metabolism parameters, and with lipids. GH, but not @entity442 , was negatively associated with all @entity1386 depots (visceral, trunk, limbs, and total) (0.41  <= r  <= 0.61, p < 0.001 for all) and positively associated with @entity14288 (r = 0.31, p = 0.013). Fat deposition after treatment was predominantly located on trunk and visceral depots. The lipid profile partially improved, with increases in HDL and @entity1675 and a decrease in Lp(a). @entity14288 decreased and @entity37462 increased. @entity1254 and leptin did not significantly change. The improvement in HOMA-IR was best predicted by the decreases in @entity442 and @entity14288 and the lack of trunk fat increase (R(2) = 0.59, p = 0.001). Conclusions: (1) @entity1386 was a metabolic risk factor for @entity1 with active @entity2012 ; (2) @entity14288 and @entity37462 were influenced by the disease activity but were not associated with @entity1386 mass; (3) fat deposition after treatment was predominantly on the trunk and visceral depots; and (4) insulin resistance decreased and the lipid profile partially improved with treatment.    2015 S. Karger AG, Basel.
